Chemocentryx Stock Today


USD 51.04  0.23  0.45%   

Market Performance
0 of 100
Odds Of Distress
Less than 1
Chemocentryx is trading at 51.04 as of the 16th of August 2022. This is a 0.45 percent increase since the beginning of the trading day. The stock's open price was 50.81. Chemocentryx has a very small chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. Equity ratings for Chemocentryx are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 17th of July 2022 and ending today, the 16th of August 2022. Click here to learn more.
Fiscal Year End
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
8th of February 2012
Health Care
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California. The company has 70.03 M outstanding shares of which 6.56 M shares are currently shorted by private and institutional investors with about 5.43 trading days to cover. More on Chemocentryx

Moving together with Chemocentryx

0.65ACXPAcurx Pharmaceuticals Earnings Call  TodayPairCorr

Moving against Chemocentryx

0.58ADMTAdm Tronics Unlimited Earnings Call  This WeekPairCorr
0.57AYTUAytu Biopharma Fiscal Year End 26th of September 2022 PairCorr
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores

Chemocentryx Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Chemocentryx's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Chemocentryx or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Chemocentryx is way too risky over 90 days horizon
Chemocentryx appears to be risky and price may revert if volatility continues
Chemocentryx is unlikely to experience financial distress in the next 2 years
The company reported the previous year's revenue of 27.33 M. Net Loss for the year was (140.65 M) with loss before overhead, payroll, taxes, and interest of (51.07 M).
Chemocentryx currently holds about 340.6 M in cash with (45.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.78.
Chemocentryx has a poor financial position based on the latest SEC disclosures
Over 80.0% of the company shares are held by institutions such as insurance companies
Latest headline from Amgen adds potential blockbuster drug with 3.7 billion ChemoCentryx deal - Saltwire
ChairmanThomas Schall
Thematic IdeaCancer Fighters (view all)
Fama & French Classification
Average Analyst Recommendation
Analysts covering Chemocentryx report their recommendations after researching Chemocentryx's financial statements, talking to executives and customers, or listening in on Chemocentryx's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Chemocentryx. The Chemocentryx consensus assessment is calculated by taking the average forecast from all of the analysts covering Chemocentryx.
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Chemocentryx based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Chemocentryx financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares63.3 M69.9 M
Moderately Down
Slightly volatile
Weighted Average Shares Diluted63.4 M69.9 M
Moderately Down
Slightly volatile
Net Cash Flow from Operations(77.6 M)(75.6 M)
Fairly Down
Slightly volatile
Total Assets342.6 M425.7 M
Significantly Down
Slightly volatile
Total Liabilities118.7 M139.5 M
Fairly Down
Slightly volatile
Current Assets240.2 M269.2 M
Fairly Down
Slightly volatile
Current Liabilities51.6 M63 M
Significantly Down
Slightly volatile
Total Debt76 M70.5 M
Significantly Up
Slightly volatile
Return on Average Assets(0.31)(0.285)
Significantly Down
Gross Margin0.940.991
Notably Down
Slightly volatile
Asset Turnover0.07180.07
Fairly Up
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Chemocentryx's available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Not RatedUndervalued
Financial Strength
Chemocentryx's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Chemocentryx's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Chemocentryx's financial leverage. It provides some insight into what part of Chemocentryx's total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Chemocentryx's books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Chemocentryx deploys its capital and how much of that capital is borrowed.
Chemocentryx cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 73.86 M in liabilities with Debt to Equity (D/E) ratio of 0.28, which may suggest the company is not taking enough advantage from borrowing. Chemocentryx has a current ratio of 5.01, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Chemocentryx until it has trouble settling it off, either with new capital or with free cash flow. So, Chemocentryx's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Chemocentryx sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Chemocentryx to invest in growth at high rates of return. When we think about Chemocentryx's use of debt, we should always consider it together with cash and equity.

Operating Cash Flow

(77.61 Million)
Chemocentryx (CCXI) is traded on NASDAQ Exchange in USA. It is located in 835 Industrial Road, Suite 600, San Carlos, CA 94070, United States and employs 178 people. Chemocentryx is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with current market capitalization of 3.55 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Chemocentryx's market, we take the total number of its shares issued and multiply it by Chemocentryx's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Chemocentryx conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 70.03 M outstanding shares of which 6.56 M shares are currently shorted by private and institutional investors with about 5.43 trading days to cover. Chemocentryx currently holds about 340.6 M in cash with (45.22 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.78.
Check Chemocentryx Probability Of Bankruptcy
Chemocentryx retains a total of 70.03 Million outstanding shares. The majority of Chemocentryx outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Chemocentryx to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Chemocentryx. Please pay attention to any change in the institutional holdings of Chemocentryx as this could imply that something significant has changed or about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.

Ownership Allocation (%)

Check Chemocentryx Ownership Details

Chemocentryx Stock Price Odds Analysis

What are Chemocentryx's target price odds to finish over the current price? In reference to a normal probability distribution, the odds of Chemocentryx jumping above the current price in 90 days from now is near 1%. The Chemocentryx probability density function shows the probability of Chemocentryx stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Chemocentryx has a beta of 0.6254 suggesting as returns on the market go up, Chemocentryx average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Chemocentryx will be expected to be much smaller as well. In addition to that, the company has an alpha of 2.2456, implying that it can generate a 2.25 percent excess return over DOW after adjusting for the inherited market risk (beta).
  Odds Below 51.04HorizonTargetOdds Above 51.04
99.59%90 days
Based on a normal probability distribution, the odds of Chemocentryx to move above the current price in 90 days from now is near 1 (This Chemocentryx probability density function shows the probability of Chemocentryx Stock to fall within a particular range of prices over 90 days) .

Chemocentryx Historical Income Statement

Chemocentryx Income Statement is one of the three primary financial statements used for reporting Chemocentryx's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Chemocentryx revenue and expense. Chemocentryx Income Statement primarily focuses on the company's revenues and expenses during a particular period.
Chemocentryx Operating Expenses is most likely to increase significantly in the upcoming years. The last year's value of Operating Expenses was reported at 161.84 Million. The current Revenues is estimated to increase to about 37.1 M, while Consolidated Income is projected to decrease to (135.2 M). View More Fundamentals

Chemocentryx Stock Against Markets

Picking the right benchmark for Chemocentryx stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Chemocentryx stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Chemocentryx is critical whether you are bullish or bearish towards Chemocentryx at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Chemocentryx without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Fundamentals Comparison Now


Fundamentals Comparison

Compare fundamentals across multiple equities to find investing opportunities
All  Next Launch Module

Chemocentryx Corporate Directors

Chemocentryx corporate directors refer to members of a Chemocentryx board of directors. The board of directors generally takes responsibility for the Chemocentryx's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Chemocentryx's board members must vote for the resolution. The Chemocentryx board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Geoffrey Parker - Independent DirectorProfile
Joseph Feczko - Independent DirectorProfile
Thomas Edwards - Independent DirectorProfile
James Tyree - Independent DirectorProfile

Invested in Chemocentryx?

You need to understand the risk of investing before taking a position in Chemocentryx. The danger of trading Chemocentryx is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Chemocentryx is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Chemocentryx. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Chemocentryx is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Continue to Trending Equities. Note that the Chemocentryx information on this page should be used as a complementary analysis to other Chemocentryx's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.

Complementary Tools for Chemocentryx Stock analysis

When running Chemocentryx price analysis, check to measure Chemocentryx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Chemocentryx is operating at the current time. Most of Chemocentryx's value examination focuses on studying past and present price action to predict the probability of Chemocentryx's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Chemocentryx's price. Additionally, you may evaluate how the addition of Chemocentryx to your portfolios can decrease your overall portfolio volatility.
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Is Chemocentryx's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Chemocentryx. If investors know Chemocentryx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Chemocentryx listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
3.6 B
Quarterly Revenue Growth YOY
Return On Assets
Return On Equity
The market value of Chemocentryx is measured differently than its book value, which is the value of Chemocentryx that is recorded on the company's balance sheet. Investors also form their own opinion of Chemocentryx's value that differs from its market value or its book value, called intrinsic value, which is Chemocentryx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Chemocentryx's market value can be influenced by many factors that don't directly affect Chemocentryx's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Chemocentryx's value and its price as these two are different measures arrived at by different means. Investors typically determine Chemocentryx value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Chemocentryx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.